Nuanced discussion of first line treatment options in advanced gastroesophageal cancer at Great Debates & Updates in Gastrointestinal Malignancies Ryan Moy Brian Labadie, MD Sam Cytryn Great Debates Herbert Irving Comprehensive Cancer Center

Very excited to be receiving a Conquer Cancer ASCO Young Investigator Award to support my research with Gulam Abbas Manji and Benjamin Izar Conquer Cancer, the ASCO Foundation

Excited to be presenting a rapid oral abstract evaluating clinical trial entry criteria in molecular therapy trials at the Quality Care/Health Services Research ASCO session this Monday 6/3 1:15 -2:45 PM CDT. Benjamin Herzberg, Margaux Dawn Hershman

Presenting a trials in progress poster of our phase II randomized controlled trial of gemcitabine and nab paclitaxel with or without anti-PD1 and CXCR4 inhibition in treatment naïve metastatic pancreatic cancer. Gulam Abbas Manji Herbert Irving Comprehensive Cancer Center ASCO

Great to be part of a community of brilliant and determined cancer researchers. Alissa Michel Lindor Qunaj @mshughes_md Kristine Lacuna, MD

Looking forward to presenting our findings this afternoon ASCO in S102! Margaux Benjamin Herzberg Herbert Irving Comprehensive Cancer Center

Very grateful to have had to opportunity to work on this project with Margaux Benjamin Herzberg Brian Henick Dawn Hershman

Congratulations to my ⭐️⭐️ co-fellow and Conquer Cancer, the ASCO Foundation Merit and YIA recipient Michael May on an excellent oral presentation at #ASCO2024! We are SO proud of you and we look forward to watch your rising trajectory! Herbert Irving Comprehensive Cancer Center NewYork-Presbyterian

Wonderful ASCO weekend with my brilliant cofellows. So happy to see them get much deserved recognition for their exciting and innovative research. Kristine Lacuna, MD Michael Hughes Margaux Lindor Qunaj Alissa Michel Herbert Irving Comprehensive Cancer Center

Are eligibility criteria hindering trial participation from patients who could receive the drug post FDA approval? Key takeaways from a study by Michael May and Margaux presented at #ASCO24 addressed this issue in the context of KRAS G12C inhibitors.

Eight Columbia oncological physicians, scientists, and trainees have been awarded Conquer Cancer, the ASCO Foundation grants/awards to recognize and advance their impact on cancer research- Congratulations to these awardees, recognized at #ASCO24 !

Completed my second 50k Velocity Ride to support research at Herbert Irving Comprehensive Cancer Center. So grateful to everyone who contributed! Honored to have received the 'Mark Heaney Hero Award' in honor of our late program director - a brilliant and kind physician who was one of my heroes.

Thank you to the Hope Foundation The Hope Foundation for Cancer Research for sponsoring my attendance at the SWOG Cancer Research Network 2024 Spring and Fall meetings! A tremendous opportunity to learn and meet talented and engaged oncologists, statisticians and advocates. Dawn Hershman Herbert Irving Comprehensive Cancer Center David Horowitz

Excited to present the updated clinical and translational results of our pilot study of motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in untreated metastatic pancreatic cancer. Gulam Abbas Manji Brian Labadie, MD Peter Shahinian, MD Herbert Irving Comprehensive Cancer Center

Another fun and enlightening ASCO with friends and colleagues Michael Hughes Kristine Lacuna, MD Lindor Qunaj Herbert Irving Comprehensive Cancer Center

A lot of positive interest about our study indicating that G12C inhibitor trials can relax renal and CNS metastasis inclusion criteria without compromising patient outcomes Benjamin Herzberg Kathryn C. Arbour Christine Garcia, MD, MPH Dawn Hershman Herbert Irving Comprehensive Cancer Center

Lots of exciting research presented at PanCAN Scientific Summit and AACR Pancreas. Great to be here with my new Memorial Sloan Kettering Cancer Center pancreas team. Wungki Park, MD MS Eileen M O’Reilly Junmin Song, MD, MS Marc Hilmi

Fascinating approach to defining the HRD immune phenotype and correlating TIME changes with patient outcomes in the POLAR trial by Marc Hilmi and Wungki Park, MD MS at Memorial Sloan Kettering Cancer Center

Since Balazs Halmos highlighted it, a good opportunity to share recent work in JNCI about which patients are eligible for KRAS G12C inhibitor clinical trials, led by Margaux and Michael May: pubmed.ncbi.nlm.nih.gov/40845174/